Key result
Soluble guanylate cyclase stimulators such as vericiguat warrant further investigation in optimally treated, low-risk patients with heart failure with reduced ejection fraction.
Why the study?
The VICTORIA trial evaluated vericiguat only in HFrEF patients with recently worsening disease, leaving its effects in lower-risk, clinically stable patients uncertain.
Should soluble guanylate cyclase (sGC) stimulators be evaluated in lower-risk, clinically stable patients with HFrEF?
Should soluble guanylate cyclase (sGC) stimulators be evaluated in lower-risk, clinically stable patients with HFrEF?
There is a strong pathophysiological and clinical rationale to investigate the efficacy of sGC stimulators like vericiguat in stable, lower-risk HFrEF patients.
No takes yet. Share an insight, caveat, or question.
Highlights evidence gap in stable HFrEF; leaves open benefit of sGC stimulators in low-risk patients.
Butler et al. (2022) conducted a review in Heart failure with reduced ejection fraction (HFrEF). Soluble guanylate cyclase (sGC) stimulators (vericiguat) was evaluated. Soluble guanylate cyclase stimulators such as vericiguat warrant further investigation in optimally treated, low-risk patients with heart failure with reduced ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: